Routine cervical cytology cancer screening should be delayed until age 21, according to guidelines released Nov. 20 by the American College of Obstetricians and Gynecologists. ACOG previously recommended that screening begin three years after first sexual intercourse or by age 21. The updated guidelines also call for women 21-30 to be screened less often - every two years instead of annually, using either the standard Pap test or liquid-based cytology. In a Practice Bulletin to be published in the December issue of Obstetrics & Gynecology, AGOG explains that "the recommendation to start screening at 21 years regardless of the age of onset of sexual intercourse is based in part on the very low incidence of cancer in younger women," as well as the potential for adverse effects associated with follow-up of young women with abnormal cytology screening results. Screening can jump to every three years in women 30 and older who have had three consecutive cervical cytology test results that are negative for intraepithelial lesions and malignancy, ACOG notes. Women with defined risk factors may benefit from more frequent screening, the guidelines state
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.
The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.
The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.
